Keywords: cardio-oncology; cardiotoxicity; imaging; CAD; coronary artery disease; CMR; cardiac magnetic resonance; CTRCD; cancer therapeutics-related cardiac dysfunction; EDV; end-diastolic volume; ERNA; equilibrium radionuclide angiocardiography; ESV; end-systolic